By Krista Lamb As the director of the Pacific Parkinson’s Research Centre at the University of British Columbia, Dr. Martin … Read More
New research points to new possibilities in young onset Parkinson’s treatments
More than 20 years after the discovery of the parkin gene, linked to young onset Parkinson’s disease, researchers at the … Read More
A researcher’s perspective on the future of Parkinson’s research
At the end of March, Parkinson Canada hosted a two-day discussion on the current and future states of Parkinson’s research. … Read More
New priorities in Parkinson’s research
At the end of March, Parkinson Canada hosted a two-day discussion on the current and future states of Parkinson’s research. … Read More
Biomarkers as the next big breakthrough in diagnosis and tracking of progression: A patient advocate’s perspective
Dr. Soania Mathur’s process of diagnosis was comparatively easy. She received a quick referral to a specialist and within 15 … Read More
Data-sharing may help advance personalized medicine therapies for Parkinson’s
For Dr. Davide Martino, who leads the Calgary Parkinson Research Initiative (CaPRI), patient involvement in research is vital. “They can … Read More
Research, clinical and other emerging trends in Parkinson’s meeting
On March 26 and 27, 2020, we are hosting a virtual meeting with leading Canadian researchers, clinicians and patients to … Read More
Julie Wysocki speaks at University of Manitoba Café Scientifique
Julie Wysocki, Director Research Program and Partnerships who leads Parkinson Canada’s National Research Program will be moderating UM’s Café Scientifique … Read More
New research shows gut fungi are not associated with Parkinson’s
Since 2014, researchers such as Dr. Silke Appel-Cresswell have been studying the gut as a key area in potentially unravelling … Read More
BlueRock Therapeutics in Collaboration with Memorial Sloan Kettering Cancer Center Receives IND Clearance for DA01 in Parkinson’s Disease
BlueRock Therapeutics shared a news release on January 7, 2020 announcing the funding of a two-year trial using adult donor … Read More